CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Histogen Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Histogen Inc.
231 Market Place
Suite 373
Phone: (858) 526-3100p:858 526-3100 San Ramon, CA  94583  United States Ticker: HSTOHSTO
Filed for Bankruptcy on 4/18/2024
This company ceased filing statements with the SEC on 1/4/2024.
Case #24-01357, filed in the U.S. Bankruptcy Court for the Southern District of California (San Diego)
Business Summary
Histogen Inc., also known as Conatus Pharmaceuticals Inc., is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board Daniel L.Kisner 76 3/10/2023 2/10/2014
President, Chief Executive Officer, Chief Financial Officer Susan A.Knudson 59 10/1/2023 5/27/2020
Independent Director David H.Crean 58 3/10/2023 5/6/2020
3 additional Officers and Directors records available in full report.

Business Names
Business Name
CNAT
Histogen Inc
Histogen Therapeutics, Inc., formerly Histogen Inc.
HSTO
Idun Pharmaceuticals

General Information
Number of Employees: 7 (As of 12/31/2022)
Outstanding Shares: 4,271,759 (As of 11/9/2023)
Shareholders: 101
Stock Exchange: OTC
Federal Tax Id: 203183915
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 24, 2024